Shire's New Product Portfolio Delivers Strong Quarterly P...(se in the treatment of ulcerative c...)

ulcerative colitis in certain European Union ("EU") countries during

2008 and 2009;

- FIRAZYR(R) (icatibant) which was launched in Germany and the UK in Q3,

following the receipt of marketing authorization from the European

Commission. Launches will continue across Europe as reimbursement

negotiations proceed. FIRAZYR has orphan designation and is the first

hereditary angiodema ("HAE") product to receive approval throughout the

European Union;

- INTUNIV(TM) (guanfacine) for use in children and adolescents

in the US in 2009;

- FOSRENOL(R) (lanthanum carbonate) in the pre-dialysis Chronic Kidney

Disease ("CKD") market in the US in 2009 subject to ongoing discussions

with the FDA regarding regulatory pathway for approval;

- DAYTRANA(R) (methylphenidate transdermal system) for use in

children in the EU in 2009 and adolescents in the US in 2010; and

- Velaglucerase alfa for the treatment of Gaucher disease in

the US and the EU in 2010.

Update on Current Portfolio

VYVANSE(R) (lisdexamfetamine dimesylate) - Attention Deficit and Hyperactivity Disorder ("ADHD")

- The launch of VYVANSE for adult ADHD in June 2008 has helped to make

VYVANSE the third highest prescribed ADHD product in the US. For the

nine months to September 30, 2008 VYVANSE net sales totaled $215.6

million.

- On July 2, 2008 Shire shipped to wholesalers stocks of three additional

dosage strengths (20mg, 40mg and 60mg) for VYVANSE representing product

sales of approximately $24 million. These net product sales have been

recognized into revenue in Q3 2008.

FOSRENOL(R) -Hyperphosphatemia

- FOSRENOL was approved in Japan in October 2008. Shire's out-licensee,

Bayer Yakuhin Limited, is now progressing pricing and reimbursement

negotiations in that ma
'/>"/>